Swedish biotech Gabather has received the approval from the Portuguese authorities to go ahead with a target engagement study to complete the phase I evaluation of GT-002, the company’s candidate targeting mood disorders. As patient recruitment for the study proceeds, BioStock got in touch with CEO Michael-Robin Witt to learn
Läs merAktieportföljen Live 2021-11-27
Hör Michael Robin Witt (CEO) presentera Gabather hos Aktieportföljen Live den 24e november 2021.
Läs merBiostock: Gabather poised to complete phase I with GT-002
Aktiespararna: Aktiedagen Stockholm
VD Michael-Robin Witt presenterar Gabather på Aktiespararnas Aktiedagen i Stockholm 7 september 2021
Läs merCEO ANFÖRANDE PÅ ÅRSSTÄMMAN 2021
BioStock Life Science Spring Summit 2021
CEO Michael-Robin Witt presents Gabather at the spring edition of BioStock Life Science Summit 2021.
Läs merBiostock: Covid unmasks need for better mental health medication
As researchers continue working around the clock to put together the puzzle pieces needed for better understanding Covid-19 pathology, the disease has further exposed a serious lack of treatments for mental health conditions. In Sweden, biotech Gabather is developing new treatments for CNS diseases, including psychiatric disorders that appear in many
Läs merBioStock Studio: Gabather gives clinical trial update
BioStock Studio: Gabather gives clinical trial update – BioStock
Läs merFinWire: Aktieportföljen Live 10 Mars
Biostock: Q4 report points to progress in the clinic for Gabather
Last week, Gabather published its 2020 year-end report, which shows that the company is ramping up its clinical development with GT-002. Going forward the company will focus on studying the effects of its top candidate on brain activity, which will be a key step in determining dosage of GT-002 to
Läs mer